Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.
Press releases published on May 7, 2025
Symbotic Reports Second Quarter Fiscal Year 2025 Results
GlobeNewswire
·
May 7, 2025
WILMINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, announced financial results for its second quarter of fiscal year 2025, which ended on March 29, 2025. …
RENEW Energy Partners Named 2025 Climate Finance Innovator by U.S. Department of Energy Better Buildings Initiative
GlobeNewswire
·
May 7, 2025
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- RENEW Energy Partners has been named a 2025 Climate Finance Innovator Award recipient by the U.S. Department of Energy’s Better Buildings Initiative. This annual award recognizes organizations pioneering new …
Risk Strategies Annual Education Practice Student Health Plan Survey Finds Costs Rising Nationwide
GlobeNewswire
·
May 7, 2025
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Risk Strategies, a leading national specialty insurance brokerage and risk management and consulting firm, today released the findings of its Annual Student Health Plan Benchmarking Survey. For the fourth …
MKS Breaks Ground on New Chemical Manufacturing and TechCenter Facility in Thailand
GlobeNewswire
·
May 7, 2025
ANDOVER, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- MKS Instruments. Inc. (NASDAQ: MKSI) (“MKS”), a global provider of enabling technologies that transform our world, announced today the groundbreaking of its cutting-edge Atotech chemical manufacturing and …
Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
GlobeNewswire
·
May 7, 2025
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced additional data from its Phase 2 clinical study ( …
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
GlobeNewswire
·
May 7, 2025
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 …
Advent Technologies Announces Bryan Holasek as Chief Strategy Officer
GlobeNewswire
·
May 7, 2025
LIVERMORE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Advent Technologies Holdings, Inc. (NASDAQ: ADN) ("Advent "or the "Company"), an innovation-driven leader in the fuel cell and hydrogen technology sector, is pleased to announce that Bryan Holasek has …
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
GlobeNewswire
·
May 7, 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of …
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire
·
May 7, 2025
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a …
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in …
Repligen Corporation to Present at Upcoming May Investor Conferences
GlobeNewswire
·
May 7, 2025
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC …
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 7, 2025
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease …
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
GlobeNewswire
·
May 7, 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the …
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
GlobeNewswire
·
May 7, 2025
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, analysis showed improvements in both …
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
May 7, 2025
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for …
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product sales SYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by …
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
GlobeNewswire
·
May 7, 2025
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When …
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Worldwide revenue of $372.8 million in the first quarter 2025 GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024 …
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
GlobeNewswire
·
May 7, 2025
– Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected …
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
GlobeNewswire
·
May 7, 2025
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer’s disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE …